SCHEMBL17455956

SCHEMBL17455956

O=C(CN1CCC(Oc2cccnc2-c2ccncc2)CC1)N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TMEM97 Q5BJF2 2/20 0.51
▸ SIGMAR1 Q99720 1/20 0.51
▸ NAMPT P43490 1/20 0.43
▸ MKNK1 Q9BUB5 1/20 0.43
▸ MKNK2 Q9HBH9 1/20 0.43
▸ PTGS2 P35354 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ LRRK2 Q5S007 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ TLR9 Q9NR96 1/20 0.40
▸ TLR8 Q9NR97 1/20 0.40
▸ TLR7 Q9NYK1 1/20 0.40
▸ MAPK3 P27361 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ MAP2K2 P36507 1/20 0.40
▸ MAP2K1 Q02750 1/20 0.40
▸ MAPK6 Q16659 1/20 0.40
▸ RBP4 P02753 1/20 0.40
▸ SMO Q99835 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17456003 0.91 RBP4 (0.41) TMEM97SIGMAR1ALDH1A1SMN1; SMN2GAA
SCHEMBL17455922 0.91 ALDH1A1 (0.43) TMEM97SIGMAR1PTGS2ALDH1A1SMN1; SMN2
SCHEMBL17456025 0.87 TMEM97 (0.53) TMEM97SIGMAR1NAMPTPTGS2ALDH1A1
SCHEMBL17456015 0.81 CDK9 (0.42) TLR9TLR8TLR7RBP4
SCHEMBL17505977 0.81 ERBB2 (0.44) ALDH1A1TLR9TLR8TLR7RBP4
SCHEMBL17455940 0.81 NAMPT (0.46) NAMPTALDH1A1RBP4
SCHEMBL17456068 0.79 KDM4E (0.45) ALDH1A1TLR9TLR8TLR7RBP4
SCHEMBL17456063 0.79 TMEM97 (0.48) TMEM97SIGMAR1NAMPTMKNK1MKNK2
SCHEMBL17456064 0.77 RBP4 (0.47) NAMPTRBP4
SCHEMBL17455932 0.77 NAMPT (0.45) NAMPTLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 TMEM97 4048/4885SIGMAR1 3212/4885NAMPT 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback